Breakthrough Products

Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients’ lives to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases.

Renibus’ first-in-class lead program, RBT-1 (SnPP / FeS), is a potent inducer of Nrf2, IL-10, and ferritin. RBT-1 is currently in Phase 2 development in cardiac surgery and will soon enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications following cardiothoracic surgery. RBT-2 is an antioxidant and anti-fibrotic drug that has been shown to reduce the risk of CKD progression in preclinical models. RBT-3 (FeS), a novel, low molecular weight iron nanoparticle, is one component of RBT-1 and is targeted at reducing the risk of cisplatin-induced nephrotoxicity and will be in clinical development in 2023. RBT-9, a potent anti-inflammatory and anti-oxidant, is in early-stage development to mitigate the progression of NASH.

Learn more about our approach and our pipeline.

Our Pipeline

Featured News

Go to Top